How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week High
BridgeBio Pharma hit a 52-week high after a rival's phase III setback boosts confidence in Attruby's competitive position in ATTR-CM.
BBIO - BridgeBio Pharma, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$104.60
DETAILS
HIGH:
$157.00
LOW:
$83.00
MEDIAN:
$100.00
CONSENSUS:
$104.60
UPSIDE:
22.14%
Stock News
BridgeBio Pharma (BBIO) Moves 15.1% Higher: Will This Strength Last?
BridgeBio Pharma (BBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
BridgeBio Stock Taps Rare Disease Trends and New Diagnosis Growth
BBIO builds on Attruby's launch as rising rare disease diagnoses and late-stage pipeline candidates set up multiple potential U.S. launches.
BridgeBio Stock Outlook Hinges on Attruby & New Drug Catalysts
BBIO's outlook hinges on Attruby growth, upcoming drug launch catalysts and execution as it seeks to diversify beyond its lone marketed therapy.
Is BBIO Stock a Buy Now or Too Expensive for the Risk Ahead
BridgeBio Pharma BBIO has become a harder stock to judge after its sharp rare-disease run. Attruby is ramping quickly, yet the valuation already assumes a good deal of future success.
Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM
- Acoramidis initiation was associated with rapid kidney-protective activity as exhibited in a hemodynamically mediated, reversible eGFR dip and a placebo-corrected 15.5% reduction in UACR by Day 28 (P
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
- Preferred equity investment led by Sixth Street and with participation from HealthCare Royalty, a business of KKR, with an initial conversion price of approximately $138 per share (more than 100% premium to Company's 30-day VWAP)
BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia
- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-breaking oral presentation; presentation includes new arm span Z-score data showing a statistically significant improvement versus placebo (LS mean +0.37 SD; p
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on June 18, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 30 new employees in restricted stock units for an aggregate of 66,810 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on May 16, 2027, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates.
BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
PALO ALTO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional positive data from PROPEL 3, the global Phase 3 pivotal study of oral infigratinib in children living with achondroplasia, will be shared in a late breaking oral presentation at the International Congress of Children's Bone Health (ICCBH) 2026 taking place in Montreal, Canada on June 27-30, 2026.
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Boyd Gaming, Chipotle Mexican Grill, Conagra, Dollar General, MGM Resorts International, Omnicom Group, Yum! Brands, and More
Mid-Day Stocks: Stocks are trading lower on Wednesday, as oil and yields move higher. Once again, it was "Welcome back, my friends to the show that never ends." On cue, the never-say-die stock market shook off early worries and all the major indices closed higher on Tuesday. Like the proverbial broken record, the S&P 500... Here Are Wednesday's Top Wall Street Analyst Research Calls: Boyd Gaming, Chipotle Mexican Grill, Conagra, Dollar General, MGM Resorts International, Omnicom Group, Yum! Brands, and More
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval; being granted Priority Review by the FDA reiterates the serious unmet need for treatment options for the LGMD2I/R9 community
Citi Initiates BridgeBio at Neutral: Why the Cardiomyopathy Story Isn't a Slam Dunk
BridgeBio Pharma (NASDAQ:BBIO | BBIO Price Prediction) received a Neutral initiation from Citi Neutral on Tuesday, reflecting a measured stance on the company's transthyretin amyloid cardiomyopathy (ATTR-CM) franchise.
BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches
BridgeBio Pharma NASDAQ: BBIO executives used a BofA healthcare conference appearance in Las Vegas to reiterate confidence in the commercial trajectory of Attruby and outline expectations for three potential near-term product launches from the company's late-stage pipeline.
BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 Transcript
BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 Transcript
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1 - All pre-specified primary and key secondary efficacy endpoints were met in the Phase 3 CALIBRATE trial; 76% of participants administered encaleret achieved both serum and urine calcium within the respective target ranges at Week 24 compared to 4% when on conventional therapy at Week 4 (p<0.
Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif. , May 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on May 6, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 52 new employees in restricted stock units for an aggregate of 115,007 shares of the Company's common stock.
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on May 6, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 52 new employees in restricted stock units for an aggregate of 115,007 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on May 16, 2027, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates.
Price Targets
BridgeBio Pharma (BBIO) PT Lowered to $96 at Mizuho
$96.00
(was $68.00)
Salim Syed
·
Mizuho Securities
BridgeBio initiated with a Buy at Canaccord
$104.00
(was $63.88)
Canaccord Genuity
BridgeBio price target raised to $98 from $94 at Morgan Stanley
$98.00
(was $65.59)
Morgan Stanley
BridgeBio price target raised to $110 from $100 at H.C. Wainwright
$110.00
(was $67.39)
H.C. Wainwright
BridgeBio price target raised to $130 from $125 at Evercore ISI
$130.00
(was $66.53)
Evercore ISI
BridgeBio price target raised to $114 from $100 at Bernstein
$114.00
(was $67.45)
Bernstein
BridgeBio price target raised to $102 from $95 at Truist
$102.00
(was $70.08)
Danielle Brill
·
Truist Financial
BridgeBio initiated with an Outperform at RBC Capital
$100.00
(was $74.14)
Luca Issi
·
RBC Capital
Leerink Partners Reiterates Outperform Rating on BridgeBio Pharma (BBIO) after data presentation: "risk/reward skewed to the upside"
$98.00
(was $68.77)
Mani Foroohar
·
Leerink Partners
BridgeBio price target raised to $95 from $86 at Truist
$95.00
(was $65.75)
Danielle Brill
·
Truist Financial
BridgeBio price target raised to $100 from $90 at H.C. Wainwright
$100.00
(was $75.25)
Raghuram Selvaraju
·
H.C. Wainwright
BridgeBio price target raised to $100 from $94 at Bernstein
$100.00
(was $76.59)
William Pickering
·
Tudor Pickering
BridgeBio price target raised to $83 from $81 at Oppenheimer
$83.00
(was $76.22)
Trevor Allred
·
Oppenheimer
BridgeBio price target raised to $100 from $85 at Jefferies
$100.00
(was $76.06)
Andrew Tsai
·
Jefferies
BridgeBio Pharma (BBIO) PT Raised to $89 at Raymond James
$89.00
(was $77.74)
Martin Auster
·
Raymond James
BridgeBio initiated with an Overweight at Barclays
$157.00
(was $77.87)
Barclays
BridgeBio price target raised to $88 from $84 at Wells Fargo
$88.00
(was $76.26)
Tiago Fauth
·
Wells Fargo
BridgeBio price target raised to $86 from $80 at Truist
$86.00
(was $74.27)
Truist Financial
BridgeBio initiated with an Overweight at Morgan Stanley
$96.00
(was $73.42)
Morgan Stanley
BridgeBio price target raised to $86 from $75 at Leerink
$86.00
(was $74.59)
Leerink Partners